US Food and Drug Administration investigators painted a portrait 20 April of an Emergent BioSolutions, Inc. facility so overwhelmed by the challenge of manufacturing drug substances for two COVID-19 vaccines that it could not prevent their cross-contamination.
The facilities were not properly sized, configured or cleaned, workers were not following procedures, and risks abounded for microbiological contamination...







